EGFR and lung adenocarcinoma: The histone deacetylase inhibitor vorinostat promotes ferroptosis in EGFR-mutant lung adenocarcinoma cells by inhibiting SLC7A11 (xCT) and enhancing the efficacy of ferroptosis inducers (Zhang et al., 2021).